Literature DB >> 7670656

Neurofibromatosis type 1: pathology, clinical features and molecular genetics.

A von Deimling1, W Krone, A G Menon.   

Abstract

Neurofibromatosis type 1 (NF1) or von Recklinghausen neurofibomatosis, is a common heritable neurocutaneous disorder. This disorder appears to affect all races, with a prevalence estimated to be 1 in 3000. Approximately half of all cases of NF1 represent new mutations. The characteristics of NF1, which include cafe-au-lait spots, neurofibromas, Lisch nodules, optic glioma, osseous lesions, macrocephaly, short stature and mental retardation suggest that the genetic lesion affects the proper development of multiple organ systems. Within the past few years, the gene causing NF1 has been identified and the protein encoded by this gene, neurofibromin, has been the subject of detailed investigation. The NF1 gene spans over 350 kb of genomic DNA and encodes a protein product of 2818 amino acids. Neurofibromin is expressed in many different tissues. It is now known that one role of neurofibromin is as a GTPase activating protein (GAP), very likely in the same pathway of signal transduction as ras. Absence of neurofibromin in mice homozygously mutant for the NF1 gene results in profound developmental abnormalities. In mice that are heterozygous for NF1, an accelerated onset of tumor formation is observed. Combined with studies of tumors from NF1 patients showing homozygous deletions in the NF1 gene, these data suggest a role for NF1 as a "tumor suppressor". Evidence suggesting other roles played by neurofibromin, in control of proliferation in some situations and differentiation in others, is gradually bringing the previously hazy picture of this genetic disorder into sharper focus.

Entities:  

Mesh:

Year:  1995        PMID: 7670656     DOI: 10.1111/j.1750-3639.1995.tb00589.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  14 in total

1.  Hereditary spinal neurofibromatosis: a rare form of NF1?

Authors:  M Poyhonen; E L Leisti; S Kytölä; J Leisti
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

2.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Gastric carcinoid: germline and somatic mutation of the neurofibromatosis type 1 gene.

Authors:  W Stewart; J P Traynor; A Cooke; S Griffiths; N F Onen; M Balsitis; A A Shah; M Upadhyaya; E S Tobias
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

4.  Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.

Authors:  T Watanabe; Y Oda; S Tamiya; K Masuda; M Tsuneyoshi
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

5.  Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.

Authors:  Jacquelyn J Roth; Mariarita Santi; Avrum N Pollock; Brian N Harding; Lucy B Rorke-Adams; Laura S Tooke; Jaclyn A Biegel
Journal:  Brain Pathol       Date:  2014-09-12       Impact factor: 6.508

6.  Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas.

Authors:  M Platten; M J Giordano; C M Dirven; D H Gutmann; D N Louis
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

7.  Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.

Authors:  V Aaltonen; P J Boström; K O Söderström; O Hirvonen; J Tuukkanen; M Nurmi; M Laato; J Peltonen
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

8.  A clinical variant of neurofibromatosis type 1: familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene.

Authors:  E Ars; H Kruyer; A Gaona; P Casquero; J Rosell; V Volpini; E Serra; C Lázaro; X Estivill
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

9.  The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Authors:  Jan Zietsch; Nicolas Ziegenhagen; Frank L Heppner; David Reuss; Andreas von Deimling; Nikola Holtkamp
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  Rapid development of optic glioma in a patient with hybrid phakomatosis: neurofibromatosis type 1 and tuberous sclerosis.

Authors:  Sami H Erbay; Stephen A Oljeski; Rafeeque Bhadelia
Journal:  AJNR Am J Neuroradiol       Date:  2004-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.